CND Life Sciences has been awarded a $4.2 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) toward a study that will evaluate the use of an alpha-synuclein skin test to aid in diagnosing Parkinson’s disease and tracking its progression. The Syn-Q clinical trial…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) recognized a Texas scientist for his contributions to Parkinson’s research and his commitment to mentoring the next generation of Parkinson’s scientists. Claudio Soto, PhD, a professor of neurology and director of the George and Cynthia Mitchell Center for Alzheimer’s…
For a 69-year-old man with advanced Parkinson’s disease, sleeping with the head of his bed elevated helped to decrease dizziness related to a sudden drop in blood pressure when he got up in the morning, according to a case reported in the Netherlands. This drop in blood pressure is…
A Phase 3 clinical trial evaluating investigational oral therapy solengepras as a treatment for Parkinson’s disease has dosed its first patient. The ARISE trial (NCT06553027) is evaluating the efficacy of solengepras as a potential add-on therapy to levodopa and other Parkinson’s medications. Patient recruitment is ongoing…
Deep brain stimulation (DBS) directed at the central part of the subthalamic nucleus (STN), a brain region important for movement, was the best option to improve balance and gait, including freezing of gait, in Parkinson’s disease, a small clinical trial suggests. Targeting the central STN with electrical stimulation…
Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a hallmark of Parkinson’s disease — across the brain, according to a new study by a team in Israel. The scientists found that a genetic variant of the TMEM16F gene…
Vivolta and Neurochase have partnered to manufacture specialized micro-catheters using the former’s medical electrospinning (MediSpin) technology to deliver therapies directly to specific brain regions for neurological conditions like Parkinson’s disease. The technology would enhance Neurochase’s Convection Enhanced Delivery (CED) system, which is designed to allow…
An investigational treatment for Parkinson’s disease known as GT-02287 safely led to a roughly 53% increase in GCase enzyme activity, as measured in dried blood spots from treated healthy adults relative to those given a placebo in a Phase 1 clinical trial, its developer, Gain Therapeutics, reported. This…
People with Parkinson’s face risks during hospital stays, even when admitted for reasons other than the neurodegenerative disease itself, leading researchers to urge hospitals and health systems to adopt better practices, such as those recommended by the Parkinson’s Foundation. “Patients with Parkinson’s disease are at increased risk for…
ACI-7104, an investigational vaccine to treat people in the early stages of Parkinson’s disease, is showing safety and tolerability in a Phase 2 clinical trial, while also inducing the production of anti-alpha-synuclein antibodies at high levels, according to interim trial findings. Being developed by AC Immune,…
Get regular updates to your inbox.
